0000875320-26-000056
SEC filingVertex Pharmaceuticals reported strong financial performance for fiscal year 2025, ending December 31, 2025. The company generated $12.00 billion in product revenues, net, with income from operations of $4.17 billion and net income of $3.95 billion. This translated to earnings per share of $15.00 (both basic and diluted). The company maintained robust cash generation, with net cash provided by operating activities of $3.63 billion. Vertex's balance sheet remained strong with total assets of $25.64 billion, including $5.08 billion in cash and cash equivalents, and shareholders' equity of $18.67 billion. The company continued significant investment in research and development ($3.91 billion) while returning capital to shareholders through $2.02 billion in common stock repurchases. No prior period figures were provided for year-over-year comparisons.
Vertex Pharmaceuticals delivered solid financial results for fiscal year 2025. The company reported $12.00 billion in product revenues, net, with income from operations of $4.17 billion. After accounting for interest income of $490.9 million, interest expense of $13.3 million, other expense of -$7.7 million, and provision for income taxes of $690.0 million, net income reached $3.95 billion. This translated to earnings per share of $15.00 on both basic and diluted bases, with 255.7 million basic shares and 258.0 million diluted shares outstanding. The company's total costs and expenses were $7.83 billion, including cost of sales ($1.65 billion), research and development ($3.91 billion), selling, general and administrative ($1.75 billion), acquired in-process research and development ($133.0 million), intangible asset impairment charge ($379.0 million), and change in fair value of contingent consideration ($2.1 million).
The filing provides only aggregate product revenues of $12.00 billion for fiscal year 2025. No segment breakdown, geographic mix, or specific growth drivers are disclosed in the provided data. The company reports product revenues, net as its primary revenue source, with no other revenues mentioned. The absence of segment data suggests Vertex operates as a single reporting segment or that segment details are not included in the provided financial data extracts.
Based on the available data, Vertex achieved strong profitability metrics. With product revenues of $12.00 billion and cost of sales of $1.65 billion, the company's gross profit would be $10.35 billion, though this calculation is not explicitly provided. Operating income was $4.17 billion, representing operating leverage despite significant investments in research and development ($3.91 billion) and selling, general and administrative expenses ($1.75 billion). The company recorded an intangible asset impairment charge of $379.0 million, which impacted operating results. No prior period margin data is provided for comparison.
Vertex generated $3.63 billion in net cash from operating activities, starting from net income of $3.95 billion and adjusting for non-cash items including stock-based compensation ($685.9 million), depreciation and amortization ($209.8 million), intangible asset impairment charges ($379.0 million), deferred income taxes (-$510.8 million), and other non-cash items (-$113.4 million). Changes in working capital provided $1.34 billion, primarily from decreases in accounts receivable ($347.3 million), inventories ($524.2 million), and prepaid expenses ($396.0 million). Investing activities used $945.4 million, mainly for purchases of available-for-sale debt securities ($6.40 billion) partially offset by sales and maturities ($5.90 billion) and property and equipment purchases ($437.6 million). Financing activities used $2.26 billion, primarily for common stock repurchases ($2.02 billion). The balance sheet shows total assets of $25.64 billion, including current assets of $11.20 billion (cash: $5.08 billion, marketable securities: $1.52 billion, accounts receivable: $2.05 billion, inventories: $1.69 billion). Total liabilities were $6.98 billion, resulting in shareholders' equity of $18.67 billion.
The provided financial data extracts do not include any forward-looking statements, management guidance, strategic priorities, or risk factor discussions. The analysis is limited to the historical financial results for fiscal year 2025 as presented in the income statement, balance sheet, and cash flow statement data. No information about future expectations, pipeline developments, regulatory milestones, or market expansion plans is available in the provided extracts.